NASDAQ:IDXG Interpace Biosciences (IDXG) Stock Price, News & Analysis → Bigger Than NVIDIA? (From Behind the Markets) (Ad) Free IDXG Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$1.19▼$1.4150-Day Range$4.75▼$10.4052-Week Range$2.57▼$10.42Volume2,124 shsAverage Volume2,989 shsMarket Capitalization$5.20 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsEarningsHeadlinesTrendsStock AnalysisCompetitorsEarningsHeadlinesTrends Get Interpace Biosciences alerts: Email Address Ad Behind the MarketsBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ONE stock you should be watching.Get the full story here >>> About Interpace Biosciences Stock (NASDAQ:IDXG)Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.Read More Ad Behind the MarketsBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ONE stock you should be watching.Get the full story here >>> IDXG Stock News HeadlinesMay 9, 2024 | globenewswire.comInterpace Biosciences Announces First Quarter 2024 Financial and Business ResultsApril 3, 2024 | seekingalpha.comPDI Under $20 Exceeds A 13% Yield With Potential Upside On The HorizonJune 18, 2024 | Weiss Ratings (Ad)Reclusive millionaire’s final warning about AmericaThis crisis that's likly to begin in this country — before the election — could be bigger and more destructive than any crisis I've ever seen. That's why, no matter what you do, make sure you watch my short video and learn the three steps you need to take right now.March 7, 2024 | msn.comInterpace Biosciences announces preliminary Q4 revenue of $10.3MMarch 7, 2024 | globenewswire.comInterpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2023 Financial and Business ResultsMarch 1, 2024 | seekingalpha.comPDI: What Lurks Under The Hood Of PIMCO's Crown JewelFebruary 22, 2024 | benzinga.comInterpace Biosciences Stock (OTC:IDXG) Dividends: History, Yield and DatesJanuary 24, 2024 | seekingalpha.comPDI: 14% Yield, But Risks Are Rising (Rating Downgrade)June 18, 2024 | Weiss Ratings (Ad)Reclusive millionaire’s final warning about AmericaThis crisis that's likly to begin in this country — before the election — could be bigger and more destructive than any crisis I've ever seen. That's why, no matter what you do, make sure you watch my short video and learn the three steps you need to take right now.January 9, 2024 | seekingalpha.comPDI Looks Like It Bottomed And Is Still Yielding Over 14%December 5, 2023 | seekingalpha.comPDI: Lag Likely To ContinueNovember 8, 2023 | finance.yahoo.comInterpace Biosciences Announces Record Third Quarter 2023 Financial and Business ResultsOctober 24, 2023 | seekingalpha.comPDI: Pain Could Be On The HorizonOctober 1, 2023 | seekingalpha.comPDI: Pricing Improves, Fundamentals Stay Poor, We UpgradeAugust 31, 2023 | seekingalpha.comPDI: 100 Big Yield CEFs, REITs, MLPs - These 3 Worth ConsideringAugust 10, 2023 | finanznachrichten.deInterpace Biosciences, Inc.: Interpace Biosciences Announces Record Second Quarter 2023 Financial and Business ResultsAugust 9, 2023 | finance.yahoo.comInterpace Biosciences Announces Record Second Quarter 2023 Financial and Business ResultsJuly 10, 2023 | finance.yahoo.comInterpace Biosciences Releases Preliminary Record Second Quarter 2023 Business Results; Updates Status of PancraGEN® ReimbursementJune 5, 2023 | finance.yahoo.comInterpace Expects to Stop Offering PancraGEN® Test Due to CMS Decision to End Reimbursement as of July 17, 2023May 13, 2023 | finanznachrichten.deInterpace Biosciences, Inc.: Interpace Biosciences Announces Record First Quarter 2023 Financial and Business ResultsMay 12, 2023 | finance.yahoo.comInterpace Biosciences Announces Record First Quarter 2023 Financial and Business ResultsMarch 28, 2023 | finanznachrichten.deInterpace Biosciences, Inc.: Interpace Biosciences Announces Full Year and Fourth Quarter 2022 Financial and Business ResultsMarch 27, 2023 | finance.yahoo.comInterpace Biosciences Announces Full Year and Fourth Quarter 2022 Financial and Business ResultsMarch 13, 2023 | seekingalpha.comPDI And PTY: Unwelcome ROC, Buyer BewareMarch 9, 2023 | financialpost.comPriestly Demolition Inc. Promotes Leaders in a Restructuring Plan Designed to Support the Expansion of the Company Across North AmericaMarch 6, 2023 | financialpost.comWestport Signs Third Global Heavy-Duty OEM Collaboration Agreement to Demonstrate H2 HPDI™ Fuel System on IC Engine PlatformFebruary 20, 2023 | seekingalpha.comPTY And PDI: Abysmal SetupsSee More Headlines Receive IDXG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Interpace Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Services Current SymbolNASDAQ:IDXG CUSIP69329V10 CIK1054102 Webwww.interpace.com Phone855-776-6419Fax862-207-7820Employees152Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$800,000.00 Net Margins2.26% Pretax Margin3.13% Return on Equity-2.03% Return on Assets9.06% Debt Debt-to-Equity RatioN/A Current Ratio0.50 Quick Ratio0.50 Sales & Book Value Annual Sales$40.21 million Price / Sales0.13 Cash Flow$0.54 per share Price / Cash Flow2.21 Book Value($14.16) per share Price / Book-0.08Miscellaneous Outstanding Shares4,370,000Free Float4,086,000Market Cap$5.20 million OptionableNot Optionable Beta0.68 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Thomas W. Burnell Ph.D. (Age 58)Pres, CEO & Director Comp: $425kMr. Thomas John Freeburg Ph.D. (Age 52)Chief Accounting Officer, CFO, Treasurer & Sec. Dr. Sydney D. FinkelsteinChief Scientific OfficerDr. Alidad Mireskandari M.B.A.Ph.D., Chief Devel. OfficerMr. Patrick KaneVP & Corp. ControllerKey CompetitorsVeracyteNASDAQ:VCYTNeoGenomicsNASDAQ:NEOLaboratory Co. of AmericaNYSE:LHQuest DiagnosticsNYSE:DGXDaVitaNYSE:DVAView All Competitors IDXG Stock Analysis - Frequently Asked Questions How were Interpace Biosciences' earnings last quarter? Interpace Biosciences, Inc. (NASDAQ:IDXG) announced its quarterly earnings results on Thursday, May, 9th. The business services provider reported $0.13 EPS for the quarter. The business services provider had revenue of $10.27 million for the quarter. Interpace Biosciences had a net margin of 2.26% and a negative trailing twelve-month return on equity of 2.03%. What other stocks do shareholders of Interpace Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Interpace Biosciences investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Histogenics (HSGX), Johnson & Johnson (JNJ), SCYNEXIS (SCYX), Cisco Systems (CSCO), Trevena (TRVN) and TherapeuticsMD (TXMD). This page (NASDAQ:IDXG) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredRadical change coming — do this NOW to protect yourselfI recently uncovered a way the government could use the next crisis as a pretext to gain more control … and ra...Weiss Ratings | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Interpace Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Interpace Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.